<DOC>
	<DOCNO>NCT01939249</DOCNO>
	<brief_summary>BIOFLOW-IV prospective , international , multicenter , randomise control trial . The purpose trial compare Biotronik Orsiro drug elute stent system Xience Prime / Xience Xpedition ( Xience ) drug elute stent system de novo coronary lesion . The study power non-inferiority respect Target Vessel Failure ( TVF ) 12 month .</brief_summary>
	<brief_title>Prospective , Randomized , Multicenter Study Assess Safety Effectiveness Orsiro Sirolimus-eluting Stent</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Main Subject must provide write informed consent The target reference vessel diameter ( RVD ) ≥ 2.50 mm ≤ 3.75 mm assess either visually online QCA . Target lesion length ≤ 26 mm ( assess either visual estimate online QCA ) cover one study stent Single de novo lesion ≥ 50 % &lt; 100 % stenosis 2 coronary artery Main Subject evidence myocardial infarction within 72 hour prior index procedure Planned intervention nontarget vessel ( ) within 30 day index procedure Planned intervention target vessel ( ) index procedure Target lesion locate leave main Target lesion locate supplied arterial venous bypass graft Target lesion involve side branch &gt; 2.0 mm diameter visual estimate online QCA Proximal distal target lesion locate stenosis might require future revascularization impede run</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>